Alvotech Makes It Four With Denosumab Trial

Study Begins For Firm’s AVT03 Proposed Prolia/Xgeva Biosimilar

 
• By Dave Wallace

Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.

Number 4 Four Pool Ball Cue
Alvotech is cueing up a fourth biosimilar clinical trial program • Source: Shutterstock

More from Biosimilars

More from Products